Pharmaceutical Product Development (PPD) has entered into a license agreement to use Tessella and Berry Consultants' adaptive trial design solution.

Comprised of a suite of programs, the FACTS solution has built-in facilities for simulating interim and final patient responses, patient dropouts and patient accrual.

Under the agreement, PPD will use the FACTS software in its adaptive trials to make adjustments to an ongoing trial based on a set of pre-specified conditions.

Pharmaceutical Product Development global biometrics senior vice president Susan Atkinson said FACTS will enhance the company's ability to deliver flexible, efficient adaptive trial designs for its clients in less time.

"The simulations generated by this software will help us create richer designs so that our clients can make better informed decisions about their trials," Atkinson added.

"This agreement also demonstrates our commitment to enhancing our position as a leader in adaptive trial design among full-service contract research organizations."

The company said the solution can also can be used in the fixed trials.